The prognostic significance of the BRAF(V600E) mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry
Penelope A McKelvie, Fiona Chan, Yong Yu, Paul Waring, Irma Gresshoff, Stephen Farrell, Richard A Williams
PATHOLOGY | ELSEVIER | Published : 2013
AIMS: BRAF mutation has been shown in a large meta-analysis to be an independent prognostic marker for papillary thyroid carcinoma (PTC) with poorer survival and higher recurrence rates. METHODS: We studied prevalence of BRAF mutation in 77 patients with PTC from an Australian cohort using competitive polymerase chain reaction (C-PCR) and immunohistochemistry (IHC) with BRAF-specific antibody, VE1. Clinicopathological parameters, recurrence and mortality were analysed according to BRAF mutation status. RESULTS: Median follow-up was 84.5 months. BRAF mutation was demonstrated in 65% of cases combining both C-PCR and IHC; in 71% (37/77) of tumours >1 cm and 52% (13/25) of microcarcinomas (45 y..View full abstract
Ventana Medical Systems provided reagents, loaned equipment and part salary to PW and IG for scientist (IG) to undertake this and other studies of the VE1 antibody. The other authors have no disclosures.